Revuforj recorded $54.7 million in net revenue, while Niktimvo generated $60 million in net sales reported by Syndax’s partner Incyte. In the fourth quarter, Syndax expects to publish data in relapsed or refractory NUP98-rearranged acute leukemia. Syndax expects to submit an investigational new drug application by the end of 2026 and anticipates an initial monotherapy activity assessment in early 2028. Syndax expects to submit an IND and start a Phase I trial in 2027. About Syndax Pharmaceuticals (NASDAQ:SNDX)Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer.